Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.86% | -9.39% | -24.07% | 19.95% | -8.80% |
| Total Depreciation and Amortization | -30.75% | 4.47% | -2.41% | -2.07% | -1.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.72% | 103.82% | 102.74% | -43.69% | 35.79% |
| Change in Net Operating Assets | -181.46% | -161.03% | 182.51% | -717.43% | 114.66% |
| Cash from Operations | -21.62% | 5.51% | 8.94% | 3.13% | 8.97% |
| Capital Expenditure | -1,120.41% | 80.20% | -870.59% | 40.70% | 52.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 91.45% | -11.72% | 148.68% | -406.45% | -61.79% |
| Cash from Investing | 87.03% | -10.39% | 147.70% | -408.26% | -61.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -90.30% | -- |
| Cash from Financing | -- | -- | -100.00% | -98.67% | 53,148.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 578.36% | 53.18% | 95.31% | -206.23% | 830.79% |